TherapeuticsMD, Inc.
Close on Oct 19, 2026
- Market cap
- $21.66M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | During market hours | $869.00K | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | During market hours | $724.00K | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 30, 2026 | During market hours | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | During market hours | $784.00K | $0.00 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | During market hours | $1.00M | $0.05 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | During market hours | $393.00K | $-0.06 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 27, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | During market hours | $547.00K | $-0.05 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 12, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 10, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 29, 2024 | During market hours | – | – | – |
Press releases
Announcements TherapeuticsMD filed with the SEC
PRESS RELEASE FROM THERAPEUTICSMD, INC., DATED AUGUST 11, 2026, ENTITLED "THERAPEUTICSMD ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS."
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE FROM THERAPEUTICSMD, INC., DATED MAY 12, 2026, ENTITLED "THERAPEUTICSMD ANNOUNCES FIRST QUARTER 2026 FINANCIAL RESULTS."
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
TherapeuticsMD Announces Full Year 2025 Financial
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE FROM THERAPEUTICSMD, INC., DATED NOVEMBER 12, 2025, ENTITLED "THERAPEUTICSMD ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS."
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE FROM THERAPEUTICSMD, INC., DATED AUGUST 12, 2025, ENTITLED "THERAPEUTICSMD ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS."
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE FROM THERAPEUTICSMD, INC., DATED MAY 13, 2025, ENTITLED "THERAPEUTICSMD ANNOUNCES FIRST QUARTER 2025 FINANCIAL RESULTS"
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE FROM THERAPEUTICSMD, INC., DATED MARCH 27, 2025, ENTITLED THERAPEUTICSMD ANNOUNCES FULL YEAR 2024 FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE FROM THERAPEUTICSMD, INC., DATED NOVEMBER 12, 2024, ENTITLED "THERAPEUTICSMD ANNOUNCES THIRD QUARTER 2024 FINANCIAL RESULTS"
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE FROM THERAPEUTICSMD, INC., DATED AUGUST 12, 2024, ENTITLED "THERAPEUTICSMD ANNOUNCES SECOND QUARTER 2024 FINANCIAL RESULTS"
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
THERAPEUTICSMD ANNOUNCES FIRST QUARTER 2024 FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE FROM THERAPEUTICSMD, INC., DATED MARCH 29, 2024, ENTITLED "THERAPEUTICSMD ANNOUNCES FULL YEAR 2023 FINANCIAL RESULTS"
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
TherapeuticsMD Announces Third Quarter 2023 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
TherapeuticsMD Announces Second Quarter 2023 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
TherapeuticsMD Announces First Quarter 2023 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
TherapeuticsMD Completes Transaction to License its Products to Mayne Pharma
Material agreement · Agreement terminated · Acquisition or disposition completed · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Update December 5, 2022 Exhibit 99.2
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
TherapeuticsMD Announces Third Quarter 2022 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
TherapeuticsMD Announces Additional $7 Million Private Placement
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
TherapeuticsMD Announces $7 Million Private Placement
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
TherapeuticsMD Announces Second Quarter 2022 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
FOR INVESTOR PRESENTATION PURPOSES ONLY. Building the Premier
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital
Material agreement · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
TherapeuticsMD and EW Healthcare Partners
Material agreement · Other events · EX-99.1 to Form 8-K
TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA®
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
TherapeuticsMD Announces First Quarter 2022 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Building the Premier Women’s Health Company Q1 2022 Earnings
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
TherapeuticsMD completes the divestiture of vitaCare Prescription Services to GoodRx in a cash transaction valued at $150 million
Regulation FD disclosure · EX-99.1 to Form 8-K
TherapeuticsMD Announces Fourth Quarter 2021 Financial Results
Material agreement · Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Building the Premier Women’s Health Company Q4 2021 Earnings
Material agreement · Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
TherapeuticsMD Enters into a Definitive Agreement to Divest vitaCare to GoodRx
Regulation FD disclosure · EX-99.1 to Form 8-K
U.S. Food and Drug Administration (FDA) Responds to Request from TherapeuticsMD to Revise Certain Manufacturing Testing Limits for ANNOVERA®
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
TherapeuticsMD Settles U.S. Patent Litigation with Amneal for BIJUVA ® (Estradiol and Progesterone) — Allowing for a May 25, 2032 Generic Entry Date
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Lisa Wilson; TherapeuticsMD; Investor Relations
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K/A
TherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh O’Dowd, as Chief Executive Officer
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
TherapeuticsMD Announces Third Quarter 2021 Financial Results
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Building the Premier Women’s Health Company Q3 2021 Earnings
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.3 to Form 8-K